Processa Pharmaceuticals (PCSA) Gross Profit (2012 - 2016)

Processa Pharmaceuticals (PCSA) has reported Gross Profit for 5 consecutive years, with $5000.0 the latest figure, recorded in Q1 2016.

• For the quarter ending Q1 2016, Gross Profit fell 60.92% year-over-year to $5000.0; the trailing twelve-month figure through Dec 2016 stood at $5000.0 (up 246.28% YoY), and the FY2016 full-year result was $5000.0, up 140.16% from the prior year.
• Gross Profit improved to $5000.0 in Q1 2016 per PCSA's latest filing, from -$40792.0 in the prior quarter.
• Across five years, Gross Profit topped out at $45460.0 in Q3 2013 and bottomed at -$40792.0 in Q4 2015.
• Historically, Gross Profit has averaged $13946.7 across 5 years, with a median of $13968.0 in 2012.
• The sharpest annual moves came in 2013 and 2014: Gross Profit jumped 2286.59% in 2013, then plunged 212.67% in 2014.
• Over 5 years, Gross Profit stood at -$1655.0 in 2012, then surged by 2286.59% to $36188.0 in 2013, then slumped by 212.67% to -$40774.0 in 2014, then declined by 0.04% to -$40792.0 in 2015, then jumped by 112.26% to $5000.0 in 2016.
• According to Business Quant data, Gross Profit over the past three periods registered $5000.0, -$40792.0, and $15547.0 for Q1 2016, Q4 2015, and Q3 2015 respectively.